RETINAL DETACHMENT IN EYES WITH BOSTON TYPE 1 KERATOPROSTHESIS: Surgical Techniques and Mid-Term Outcomes.


Journal

Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919

Informations de publication

Date de publication:
01 05 2022
Historique:
pubmed: 27 12 2021
medline: 29 4 2022
entrez: 26 12 2021
Statut: ppublish

Résumé

To evaluate the mid-term outcomes of pars plana vitrectomy performed for retinal detachment (RD) repair after Boston Type 1 keratoprosthesis (KPro) implantation. Retrospective review of medical records of KPro implanted at the Stein Eye Institute presenting with RD and treated by pars plana vitrectomy. Functional success was defined as a postoperative visual acuity maintained within 2 Snellen lines of the corrected distance visual acuity measured before the development of the RD (baseline) and anatomical success as an attached retina after the pars plana vitrectomy. Kaplan-Meyer survival analyses were performed. Among the 224 KPro performed, 28 (15.2%) RD were identified; of which, 21 (9.4%) were included. The mean follow-up was 42.5 ± 27.3 months. Vitreoretinal proliferation was present in 18 of 21 eyes (85.7%). Surgical techniques were adapted to the complex anterior segment anatomy of KPro eyes. Anatomical success was achieved in 18 of 21 eyes (85.7%). Functional success occurred in 17 of 21 eyes (81.0%), and 5 of 21 eyes (23.8%) reached 20/400 or better visual acuity at the final follow-up. The KPro was retained in 11 in 21 eyes (52.4%). The retention rate decreased from 94.7% at 1 year to 53.5% at 5 years. The most frequent complications were retroprosthetic membrane (47.6%) and corneal melt (23.8%). Modified pars plana vitrectomy techniques resulted in relatively good mid-term anatomical, functional, and retention rate outcomes, given the severity of RD at presentation and the numerous preoperative comorbidities of KPro eyes.

Identifiants

pubmed: 34954778
doi: 10.1097/IAE.0000000000003389
pii: 00006982-202205000-00016
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

957-966

Références

Klufas MA, Yannuzzi NA, D'Amico DJ, Kiss S. Vitreoretinal aspects of permanent keratoprosthesis. Surv Ophthalmol 2015;60:216–228.
Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 2009;116:640–651.
Goldman DR, Hubschman JP, Aldave AJ, et al. Postoperative posterior segment complications in eyes treated with the Boston type I keratoprosthesis. Retina 2013;33:532–541.
Bonnet C, Chehaibou I, Chen A, et al. Postoperative posterior segment complications after boston type 1 keratoprosthesis: incidence, risk factors, and intermediate-term outcomes. Retina 2021;41:2499–2509.
Ray S, Khan BF, Dohlman CH, D'Amico DJ. Management of vitreoretinal complications in eyes with permanent keratoprosthesis. Arch Ophthalmol 2002;120:559–566.
Harissi-Dagher M, Durr GM, Biernacki K, et al. Pars plana vitrectomy through the Boston Keratoprosthesis type 1. Eye (Lond) 2013;27:767–769.
Petrou P, Banerjee PJ, Wilkins MR, et al. Characteristics and vitreoretinal management of retinal detachment in eyes with Boston keratoprosthesis. Br J Ophthalmol 2017;101:629–633.
Rishi P, Rishi E, Koundanya VV, et al. Vitreoretinal complications in eyes with Boston keratoprosthesis type I. Retina 2016;36:603–610.
Iyer G, Srinivasan B, Agarwal S, et al. Keratoprostheses in silicone oil-filled eyes: long-term outcomes. Br J Ophthalmol 2019;103:781–788.
Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991;112:159–165.
Aravena C, Yu F, Aldave AJ. Long-term visual outcomes, complications, and retention of the boston type I keratoprosthesis. Cornea 2018;37:3–10.
Sayegh RR, Dohlman CH. Wide-angle fundus imaging through the Boston keratoprosthesis. Retina 2013;33:1188–1192.
Kornberg DL, Yannuzzi NA, Klufas MA, et al. Ultra-widefield imaging of posterior segment pathology in the setting of the boston keratoprosthesis. Retina 2016;36:1101–1110.
Francone A, Kothari N, Farajzadeh M, et al. Detection of neurosensory retinal detachment complicating degenerative retinoschisis by ultra-widefield fundus autofluorescence imaging. Retina 2020;40:819–824.
Tripathy K, Chawla R, Temkar S, et al. Phthisis bulbi-a clinicopathological perspective. Semin Ophthalmol 2018;33:788–803.
Iyer G, Srinivasan B, Gupta J, et al. Boston keratoprosthesis for keratopathy in eyes with retained silicone oil: a new indication. Cornea 2011;30:1083–1087.
Joussen AM, Wong D. The concept of heavy tamponades-chances and limitations. Graefes Arch Clin Exp Ophthalmol 2008;246:1217–1224.
Toygar O, Mestanoglu M, Riemann CD. Intraoperative ocular manometry in silicone oil-filled eyes with a boston type 1 keratoprosthesis. Retina 2019;39:2155–2160.
Enders P, Hall J, Bornhauser M, et al. Telemetric intraocular pressure monitoring after boston keratoprosthesis surgery using the eyemate-IO sensor: dynamics in the first year. Am J Ophthalmol 2019;206:256–263.
Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 1997;115:237–241.
Jardeleza MS, Rheaume MA, Chodosh J, et al. Retinal detachments after Boston Keratoprosthesis: incidence, predisposing factors, and visual outcomes. Digit J Ophthalmol 2015;21:1–15.
Kunavisarut P, Srisomboon T, Patikulsila D, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with uveitis. Ocul Immunol Inflamm 2019;27:681–685.
De Molfetta V, Bottoni F, Arpa P, et al. The effect of simultaneous internal tamponade on fluid compartmentalization and its relationship to cell proliferation. Retina 1992;12:S40–S45.
Bouhout S, Robert MC, Deli S, Harissi-Dagher M. Corneal melt after boston keratoprosthesis: clinical presentation, management, outcomes and risk factor Analysis. Ocul Immunol Inflamm 2018;26:693–699.
Chan CC, LoVerde L, Qiang J, et al. Incidence, risk factors, and surgical management of boston type 1 keratoprothesis corneal melts, leaks, and extrusions. Cornea 2016;35:1049–1056.
Iyer G, Srinivasan B, Agarwal S, et al. Keratoprostheses in silicone oil-filled eyes: long-term outcomes. Br J Ophthalmol 2018;103:781–788.
Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221–e1234.
Campo RV, Sipperley JO, Sneed SR, et al. Pars plana vitrectomy without scleral buckle for pseudophakic retinal detachments. Ophthalmology 1999;106:1811–1816.
Vilaplana F, Nadal J, Temprano J, et al. Results of retinal detachment surgery in eyes with osteo-keratoprosthesis. Retina 2018;38:2336–2342.
McCulloch DL, Loffler G, Colquhoun K, et al. The effects of visual degradation on face discrimination. Ophthalmic Physiol Opt 2011;31:240–248.

Auteurs

Clémence Bonnet (C)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.
Ophthalmology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France; and.

Ismael Chehaibou (I)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.
Ophthalmology Department, AP-HP, Hôpital Lariboisière, Université de Paris, Paris, France.

Colin A McCannel (CA)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Tara A McCannel (TA)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Pradeep S Prasad (PS)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Allan E Kreiger (AE)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Steven D Schwartz (SD)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Anthony Aldave (A)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Jean-Pierre Hubschman (JP)

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH